Companies Cryptocurrencies
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc
Exchange: Nasdaq Global Select
IPO Date: 20/07/2016
CEO: Mr. Marvin L. White
Biotechnology Healthcare 🔗
  • APVO
  • 17.26
  • 84470272
    market cap
  • -0.10000038
If you bought

shares of Aptevo Therapeutics Inc (APVO) on
You would have made
Old Price $12 Current Price $12

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)) and VARIZIG (Varicella Zoster Immune Globulin (Human)).

Address: 2401 4th Ave Ste 1050 Seattle WASHINGTON 98121

Stay updated.